-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
August J. Troendle Buys 94,119 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) Stock
August J. Troendle Buys 94,119 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) Stock
Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating) CEO August J. Troendle bought 94,119 shares of the business's stock in a transaction that occurred on Wednesday, September 21st. The shares were purchased at an average price of $161.63 per share, for a total transaction of $15,212,453.97. Following the completion of the purchase, the chief executive officer now directly owns 6,425,593 shares of the company's stock, valued at approximately $1,038,568,596.59. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Medpace Stock Down 0.6 %
MEDP traded down $0.95 on Thursday, reaching $154.83. The company's stock had a trading volume of 393,461 shares, compared to its average volume of 343,725. The stock has a 50 day moving average of $161.31 and a two-hundred day moving average of $152.71. The company has a market capitalization of $4.80 billion, a price-to-earnings ratio of 26.88 and a beta of 1.47. Medpace Holdings, Inc. has a fifty-two week low of $126.94 and a fifty-two week high of $231.00.
Get Medpace alerts:Medpace (NASDAQ:MEDP – Get Rating) last posted its quarterly earnings data on Monday, July 25th. The company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.12. The business had revenue of $351.21 million during the quarter, compared to the consensus estimate of $344.01 million. Medpace had a return on equity of 30.56% and a net margin of 16.27%. The company's revenue was up 26.2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.06 earnings per share. As a group, analysts anticipate that Medpace Holdings, Inc. will post 6.16 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on the stock. UBS Group assumed coverage on shares of Medpace in a research note on Wednesday, September 7th. They set a "sell" rating and a $142.00 target price on the stock. StockNews.com lowered shares of Medpace from a "buy" rating to a "hold" rating in a research note on Thursday, September 8th.Institutional Investors Weigh In On Medpace
Several large investors have recently modified their holdings of MEDP. Signaturefd LLC raised its position in Medpace by 486.7% in the first quarter. Signaturefd LLC now owns 264 shares of the company's stock worth $43,000 after acquiring an additional 219 shares in the last quarter. Lansing Street Advisors purchased a new position in shares of Medpace in the first quarter valued at $44,000. Point72 Hong Kong Ltd purchased a new position in shares of Medpace in the second quarter valued at $42,000. Prospera Financial Services Inc purchased a new position in shares of Medpace in the first quarter valued at $47,000. Finally, Parkside Financial Bank & Trust acquired a new stake in shares of Medpace during the second quarter valued at $50,000. Hedge funds and other institutional investors own 83.97% of the company's stock.
About Medpace
(Get Rating)
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Read More
- Get a free copy of the StockNews.com research report on Medpace (MEDP)
- What Steelcase's Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating) CEO August J. Troendle bought 94,119 shares of the business's stock in a transaction that occurred on Wednesday, September 21st. The shares were purchased at an average price of $161.63 per share, for a total transaction of $15,212,453.97. Following the completion of the purchase, the chief executive officer now directly owns 6,425,593 shares of the company's stock, valued at approximately $1,038,568,596.59. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
纳斯达克首席执行官奥古斯特·J·特伦德尔在9月21日星期三的一笔交易中购买了该公司94,119股股票。这些股票是以每股161.63美元的平均价格购买的,总交易额为15,212,453.97美元。收购完成后,首席执行官现在直接拥有6,425,593股公司股票,价值约1,038,568,596.59美元。此次收购是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过美国证券交易委员会网站.
Medpace Stock Down 0.6 %
Medace股价下跌0.6%
MEDP traded down $0.95 on Thursday, reaching $154.83. The company's stock had a trading volume of 393,461 shares, compared to its average volume of 343,725. The stock has a 50 day moving average of $161.31 and a two-hundred day moving average of $152.71. The company has a market capitalization of $4.80 billion, a price-to-earnings ratio of 26.88 and a beta of 1.47. Medpace Holdings, Inc. has a fifty-two week low of $126.94 and a fifty-two week high of $231.00.
周四,MEDP股价下跌0.95美元,至154.83美元。该公司股票的成交量为393,461股,而其平均成交量为343,725股。该股的50日移动均线切入位为161.31美元,200日移动均线切入位为152.71美元。该公司市值为48亿美元,市盈率为26.88倍,贝塔系数为1.47。Medace Holdings,Inc.股价为126.94美元,为52周低点,52周高点为231.00美元。
Medpace (NASDAQ:MEDP – Get Rating) last posted its quarterly earnings data on Monday, July 25th. The company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.12. The business had revenue of $351.21 million during the quarter, compared to the consensus estimate of $344.01 million. Medpace had a return on equity of 30.56% and a net margin of 16.27%. The company's revenue was up 26.2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.06 earnings per share. As a group, analysts anticipate that Medpace Holdings, Inc. will post 6.16 earnings per share for the current fiscal year.
MedPace(纳斯达克代码:MEDP-GET Rating)上一次公布季度收益数据是在7月25日星期一。该公司公布本季度每股收益为1.46美元,比普遍预期的1.34美元高出0.12美元。该业务本季度的收入为3.5121亿美元,而普遍预期为3.4401亿美元。Medace的股本回报率为30.56%,净利润率为16.27%。与去年同期相比,该公司的收入增长了26.2%。去年同期,该公司每股收益为1.06美元。作为一个整体,分析师预计Medace Holdings,Inc.本财年每股收益将达到6.16美元。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
Institutional Investors Weigh In On Medpace
机构投资者看好MedPace
Several large investors have recently modified their holdings of MEDP. Signaturefd LLC raised its position in Medpace by 486.7% in the first quarter. Signaturefd LLC now owns 264 shares of the company's stock worth $43,000 after acquiring an additional 219 shares in the last quarter. Lansing Street Advisors purchased a new position in shares of Medpace in the first quarter valued at $44,000. Point72 Hong Kong Ltd purchased a new position in shares of Medpace in the second quarter valued at $42,000. Prospera Financial Services Inc purchased a new position in shares of Medpace in the first quarter valued at $47,000. Finally, Parkside Financial Bank & Trust acquired a new stake in shares of Medpace during the second quarter valued at $50,000. Hedge funds and other institutional investors own 83.97% of the company's stock.
几家大型投资者最近调整了对MEDP的持股。Signaturefd LLC在第一季度将其在MedPace的头寸提高了486.7%。Signaturefd LLC在上个季度增持了219股后,现在持有264股该公司股票,价值43,000美元。Lansing Street Advisors在第一季度购买了Medace的新头寸,价值4.4万美元。Point72 Hong Kong Ltd在第二季度购买了Medpace的新股票头寸,价值42,000美元。普罗斯佩拉金融服务公司在第一季度购买了Medace的新头寸,价值4.7万美元。最后,Parkside Financial Bank&Trust在第二季度收购了Medace价值5万美元的新股。对冲基金和其他机构投资者持有该公司83.97%的股票。
About Medpace
关于MedPace
(Get Rating)
(获取评级)
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Medace控股公司在北美、欧洲和亚洲提供以临床研究为基础的药物和医疗器械开发服务。它在不同的治疗领域提供一整套服务,支持从第一阶段到第四阶段的临床开发过程。该公司还为制药、生物技术和医疗器械行业提供临床开发服务;开发计划设计、协调中心实验室、项目管理、法规事务、临床监测、数据管理和分析、药物警戒新药申请提交以及上市后临床支持服务。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Medpace (MEDP)
- What Steelcase's Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 免费获取StockNews.com关于MedPace的研究报告(MEDP)
- 斯蒂尔凯斯的收益说明了他重返办公室的原因吗?
- 这些机构持有达顿餐饮国际公司的股份
- 这三大股利支付者也拥有强劲的价格增长
- 住房建设的黄金时代已经结束了吗?
- 天然气价格继续回升,这些股票应该会受益
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
接受Medace Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯,接收对MedPace和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧